GRI Bio Inc. Company Profile
NASDAQ: GRIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
GRI Bio at a glance
GRI Bio Inc. (NASDAQ: GRI) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in La Jolla, CA. GRI Bio employs about 3 people. The company's shares have traded publicly since 2021.
At a market capitalization of $3.8 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001824293, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does GRI Bio do?
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Business description based on the company's public filings.
Company information
- Legal name
- GRI Bio Inc.
- Ticker
- NASDAQ: GRI
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 3
- Headquarters
- 2223 Avenida de la Playa, La Jolla, CA, United States
- Phone
- 619 400 1170
- Website
- gribio.com
- IPO year
- 2021
- Market cap
- $3.80M
- SEC CIK
- 0001824293
Companies similar to GRI Bio
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EOCNEocene Ltd. | 3.54 | -2.21% | $3.78M | vs GRI |
| JUNSJupiter Neurosciences Inc. | 2.85 | +2.89% | $3.76M | vs GRI |
| ERNAErnexa Therapeutics Inc. | 2.40 | -3.61% | $3.92M | vs GRI |
| CAPSCapstone Holding Corp. | 0.1372 | -2.63% | $3.62M | vs GRI |
| HCWBHCW Biologics Inc. | 1.60 | +4.58% | $3.58M | vs GRI |
| DCOYDecoy Therapeutics Inc. | 1.47 | -3.29% | $3.51M | vs GRI |
| SXTP60 Degrees Pharmaceuticals Inc. | 0.9654 | -0.73% | $3.40M | vs GRI |
| PCSAProcessa Pharmaceuticals Inc. | 1.52 | +12.59% | $4.25M | vs GRI |